Retrospective Study Evaluating The Current Utilization Of Desvenlafaxine Succinate Sustained-Release (Pristiq) Among Psychiatrists And Primary Care Physicians In The Treatment Of Patients With Major Depressive Disorder

NCT01221935 | Completed

• 2 other identifiers: 3151A1-4431B2061039
• Study Type: observational
• Target: 2,701
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this observational study is to learn about how Pristiq is currently being used in general practice and how psychiatrists and primary care physicians currently perceive Pristiq in terms of efficacy, tolerability, and adherence compared to other treatments for major depressive disorder (MDD).

Conditions

Major Depressive Disorder

Keywords

retrospective chart review study; desvenlafaxine utilization; psychiatrists and primary care physicians; treatment of major depressive disorder

Outcome Measures

Primary Outcomes (4)

• 300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment.

  6 months

• 800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a SNRI or SSRI).

  6 months

• 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a first-line treatment.

  6 months

• 800 charts including patients initiated on a SNRI or SSRI (excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).

  6 months

Secondary Outcomes (5)

• Incidence of adverse events and Incidence of discontinuation due to adverse events

  6 months

• Percent of patients experiencing relapse

  6 months

• Length of time to relapse

  6 months

• Percent of discontinuation / medication switches due to lack of efficacy

  6 months

• Subjective physician assessment of symptom control

  6 months

Study Arms (4)

Patients initiated on Pristiq as a first line treatment

Other: Pristiq first-line treatment charts

Patients initiated on Pristiq as a 2nd-line treatment

Other: Pristiq second-line treatment charts

Patients initiated on a SNRI or SSRI as a first-line treatment

Other: SNRI or SSRI first-line treatment charts

Patients initiated on a SNRI or SSRI as a 2nd-line treatment

Other: SNRI or SSRI second-line treatment charts

Interventions

Pristiq first-line treatment charts OTHER

300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment

Patients initiated on Pristiq as a first line treatment

Pristiq second-line treatment charts OTHER

800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).

Patients initiated on Pristiq as a 2nd-line treatment

SNRI or SSRI first-line treatment charts OTHER

800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.

Patients initiated on a SNRI or SSRI as a first-line treatment

SNRI or SSRI second-line treatment charts OTHER

800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).

Patients initiated on a SNRI or SSRI as a 2nd-line treatment

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

patient charts from psychiatrists and primary care physicians (PCPs) treating patients suffering from major depressive disorder (MDD).

You may qualify if:

• Patients must be adult, diagnosed with major depressive disorder and treated with pharmacotherapy.
• Physicians must be either a psychiatrist or a primary care physician, a prescriber of Pristiq, have at least 3 charts representing the 4 identified patient types, have been in clinical practice between 4 and 35 years, primarily office based (50%+), not participated in a research study relating to antidepressants or antidepressant therapy within the past month, not a consultant or have a professional relationship with a pharmaceutical company other than for clinical trials or speaking engagements, and not be employed by of affiliated with an advertising agency, market research company, or pharmaceutical company.

You may not qualify if:

• Patients who have not been treated for depression.

Sponsors & Collaborators

• Pfizer: lead

Related Links

• To obtain contact information for a study center near you, click here.

MeSH Terms

Conditions

Depressive Disorder, Major

Interventions

Serotonin and Noradrenaline Reuptake Inhibitors

Condition Hierarchy (Ancestors)

Depressive Disorder; Mood Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Neurotransmitter Uptake Inhibitors; Membrane Transport Modulators; Molecular Mechanisms of Pharmacological Action; Pharmacologic Actions; Chemical Actions and Uses; Neurotransmitter Agents; Physiological Effects of Drugs

Study Officials

• Pfizer CT.gov Call Center

  Pfizer

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: October 13, 2010
• First Posted: October 18, 2010
• Study Start: September 1, 2009
• Primary Completion: January 1, 2010
• Study Completion: January 1, 2010
• Last Updated: January 26, 2011

Record last verified: 2011-01